jueves, 9 de enero de 2020

The founder of Ionis is betting on personalized medicine in the most literal sense

The Readout
Damian Garde

The founder of Ionis is betting on personalized medicine in the most literal sense

Antisense pioneer Stanley Crooke has a new job: The former Ionis Pharmaceuticals CEO will be heading up the nonprofit n-Lorem Foundation, which aims to create N-of-1 drugs — hyper-individualized antisense oligonucleotide therapies for patients with ultra-rare diseases.

Such treatments entered the spotlight back in 2018, when Boston Children's researchers revealed they'd created a bespoke therapy for a young girl named Mila Makovec with the rare, inherited Batten's disease. News of the drug, milasen, led to an influx of patient interest — with parents of other children with such rare disorders clamoring for their own individualized treatment.

Crooke has contributed $1.5 million of his own money to the nonprofit, Chemical & Engineering News writes. Biogen has donated $1 million, and several individuals have also given money to the effort.

No hay comentarios: